HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results on May 14, 2026, underscoring significant progress in commercializing its FDA-cleared cardiac monitoring platform. The company announced the launch of initial commercial partnerships in key U.S. markets, marking a pivotal step toward widespread adoption of its innovative 3D ECG technology.
For the quarter ended March 31, 2026, HeartBeam reported a net loss of $4.7 million, an improvement from the $5.5 million net loss in the prior-year period. Research and development expenses declined year over year as the company shifted focus toward commercialization. In April 2026, HeartBeam completed a public offering that raised $11.5 million in gross proceeds, providing additional capital to support its growth initiatives.
HeartBeam is developing the first-ever cable-free device capable of collecting ECG signals in three dimensions, from three non-coplanar directions, and synthesizing them into a standard 12-lead ECG. This platform technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed for portable use outside medical facilities. Physicians can use the system to identify cardiac health trends and acute conditions, directing patients to appropriate care remotely.
The company holds over 20 issued patents related to its technology enablement and is advancing initiatives in heart attack detection and ambulatory ECG patch development. These efforts aim to expand the platform's capabilities beyond arrhythmia monitoring to include early detection of myocardial infarction and continuous cardiac surveillance.
For more details, the full press release is available at https://ibn.fm/guMCF. Information about HeartBeam's cleared indications for use is posted at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT can be found in the company's newsroom at https://ibn.fm/BEAT.
The company's forward-looking statements are subject to risks and uncertainties detailed in its SEC filings, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. HeartBeam undertakes no duty to update this information unless required by law.
